|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||155.71 - 160.79|
|52 Week Range||121.32 - 464.00|
|Beta (5Y Monthly)||-0.28|
|PE Ratio (TTM)||3.01|
|Earnings Date||Aug 08, 2022|
|Forward Dividend & Yield||2.11 (1.32%)|
|Ex-Dividend Date||Jun 02, 2022|
|1y Target Est||261.62|
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
What happened Shares of BioNTech (NASDAQ: BNTX) were up by 5.6% as of 3:24 p.m. ET Tuesday. The gain came after the Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) for the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech to include booster doses for 5- through 11-year-olds.